文献速递血栓与止血

利妥昔单抗对免疫性血小板减少症患者抗血小板自身抗体水平的影响

The effect of rituximab on anti-platelet autoantibody levels in patients with immune thrombocytopenia.
PubMed 文献 · Br J Haematol · 2017-04-25

本研究为嵌套于既往随机对照试验的病例对照研究,评估利妥昔单抗对比安慰剂对血小板自身抗体水平的影响及其与治疗反应的关系。55例可评估患者中25例(45%)基线可检测到血小板自身抗体;利妥昔单抗与抗GPIIbIIIa水平显著降低相关(P=0.02),但与抗GPIbIX水平无关(P=0.51)。基线自身抗体存在与否及治疗后自身抗体丢失均与利妥昔单抗治疗反应无关;治疗后持续存在自身抗体的患者未能达到血小板计数反应,提示血小板自身抗体持续存在可能是疾病严重程度的标志。

要点

  • 利妥昔单抗与抗GPIIbIIIa水平显著降低相关(P=0.02),与抗GPIbIX水平无关(P=0.51)。
  • 基线自身抗体存在与否及治疗后自身抗体丢失均与利妥昔单抗治疗反应无关。
  • 治疗后持续存在自身抗体的患者未能达到血小板计数反应。

核心结论

  • 利妥昔单抗与抗GPIIbIIIa水平显著降低相关,但与抗GPIbIX水平无关。
  • 基线自身抗体存在与否及治疗后自身抗体丢失均与利妥昔单抗治疗反应无关。
  • 治疗后持续存在血小板自身抗体的患者未能达到血小板计数反应,提示自身抗体持续存在可能是疾病严重程度的标志。

研究设计与样本

  • 病例对照研究,嵌套于既往一项标准治疗联合辅助利妥昔单抗或安慰剂的随机对照试验。
  • 采用抗原捕获试验检测血小板结合的抗糖蛋白(GP)IIbIIIa和抗GPIbIX。
  • 55例可评估患者中25例(45%)基线可检测到血小板自身抗体。

主要发现

  • 与安慰剂相比,利妥昔单抗与抗GPIIbIIIa水平显著降低相关(P=0.02)。
  • 与安慰剂相比,利妥昔单抗与抗GPIbIX水平降低无显著相关(P=0.51)。
  • 基线自身抗体存在与否与利妥昔单抗治疗反应无关。
  • 治疗后自身抗体丢失与利妥昔单抗治疗反应无关。
  • 治疗后持续存在自身抗体的患者未能达到血小板计数反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rituximab is an effective therapy resulting in a platelet count improvement in 60% of patients with immune thrombocytopenia (ITP). Rituximab depletes B cells; thus, a reduction in platelet autoantibody levels would be anticipated in patients who achieve a clinical response to this treatment. The objectives of this study were to determine whether rituximab was associated with a reduction in platelet autoantibody levels, and to correlate the loss of autoantibodies with the achievement of a treatment response. We performed a case-control study nested within a previous randomized controlled trial of standard therapy plus adjuvant rituximab or placebo. We measured platelet-bound anti-glycoprotein (GP) IIbIIIa and anti-GPIbIX using the antigen capture test. Of 55 evaluable patients, 25 (45%) had a detectable platelet autoantibody at baseline. Rituximab was associated with a significant reduction in anti-GPIIbIIIa levels (P = 0·02) but not anti-GPIbIX levels (P = 0·51) compared with placebo. Neither the presence of an autoantibody at baseline nor the loss of the autoantibody after treatment was associated with a response to rituximab. The subset of patients with persistent autoantibodies after treatment failed to achieve a platelet count response, suggesting that persistence of platelet autoantibodies can be a marker of disease severity.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Arnold DM, Vrbensky JR, Karim N, et al. The effect of rituximab on anti-platelet autoantibody levels in patients with immune thrombocytopenia. Br J Haematol. 2017. PMID: 28444742. doi:10.1111/bjh.14664

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。